Pfizer Inc. (NYSE:PFE) Shares Bought by S&CO Inc.

Key Points

• S&CO Inc. increased its stock holdings in Pfizer Inc. by 402.1% during the first quarter, owning 58,749 shares valued at approximately $1.49 million.
• Pfizer reported a quarterly earnings per share (EPS) of $0.92, exceeding analysts' estimates of $0.67, despite a 7.8% year-over-year revenue decline to $13.72 billion.
• Pfizer's upcoming dividend of $0.43 per share will contribute to an annualized dividend yield of 7.07%, with a dividend payout ratio of 124.64%.

S&CO Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 402.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,749 shares of the biopharmaceutical company's stock after acquiring an additional 47,049 shares during the quarter. S&CO Inc.'s holdings in Pfizer were worth $1,488,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of PFE. Clarity Asset Management Inc. purchased a new stake in Pfizer in the fourth quarter worth $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. North Capital Inc. purchased a new position in shares of Pfizer in the first quarter valued at $28,000. Bernard Wealth Management Corp. purchased a new position in shares of Pfizer in the fourth quarter valued at $30,000. Finally, Horizon Financial Services LLC purchased a new position in shares of Pfizer in the first quarter valued at $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of PFE stock traded up $0.20 during trading hours on Friday, hitting $23.49. The stock had a trading volume of 50,913,899 shares, compared to its average volume of 45,357,348. The stock's 50-day moving average price is $24.36 and its two-hundred day moving average price is $24.60. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.32. The stock has a market capitalization of $133.55 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 0.86 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.82 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on PFE shares. Wolfe Research lifted their price target on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research report on Wednesday, April 30th. Berenberg Bank reduced their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. TD Cowen reduced their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. Morgan Stanley boosted their target price on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, The Goldman Sachs Group boosted their target price on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.